

IAP20 Rec'd PGT/PTO 13 JAN 2006

Substitute for form 1449A/PTO

Complete If Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	200564620
Filing Date	Enter date here with
First Named Inventor	Prina FISHMAN
Group Art Unit	
Examiner Name	
Attorney Docket Number	FISHMAN18A

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2(m)} (known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US- 5,773,423 A	06-30-1998	Jacobson et al.	
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code ² Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS); title of article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MCH	AB	Bonvini, P. et al., "Nuclear β -catenin displays GSK-3 β - and APC-independent proteasome sensitivity in melanoma cells", Biochim. BioBiophys. Acta., (2000), Vol. 1495, pp. 308-318.	
	AC	Fang, X. et al., "Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A", Proc. Natl. Acad. Sci. (2000), Vol. 97, pp. 11960-11965.	
	AD	Ferkey, D. M., et al., "GSK-3: New Thoughts on an Old Enzyme", Dev. Biol. (2000), Vol. 225, pp. 471-479.	
	AE	Fishman, P. et al., "Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells" Oncogene, (2002), Vol. 21, pp. 4060-4064.	
	AF	Lee, Z. H., et al., "Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts", Biochemical and Biophysical Research Comm. (2003), Vol. 305, pp. 211-214.	
	AG	Olah, M. E., et al., "The role of receptor structure in determining adenosine receptor activity", Pharmacol. Ther. (2000), Vol. 85, pp. 55-75.	
	AH	Poulsen, S. et al., "Adenosine Receptors: New Opportunities for Future Drugs", Biorganic & Med. Chem. (1998), Vol. 6, pp. 619-641.	
	AI	Szabo, C. et al., "Suppression of macrophage inflammatory protein (MIP)-1 α production and collagen-induced arthritis by adenosine receptor agonists", British Journal of Pharmacology, (1998), Vol. 125, pp. 379-387.	
MCH	AJ	Walsh, N. C., et al., "Bone loss in inflammatory arthritis: mechanisms and treatment strategies", Current Opinion in Rheumatology, (2004), Vol. 16, pp. 419-427.	

Examiner
SignatureDate
Considered

1/21/08

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1
-------	---

Q

1

Application Number

Complete if Known

10/564.620

January 13, 2006

Pnina FISHMAN

1614

Not Yet Known

Attorney Docket Number

FISHMAN=18A

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]Examiner
SignatureDate
Considered

1/21/08

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.